A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Diphenoxylate and Atropine (Lomotil)

Antidiarrheal class · 8 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval1960-09-15
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.149/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.149
Across all dosage forms in distribution.
Highest NADAC
$0.149
Range is tight.
Plans with PA
115 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Diphenoxylate and Atropine used for?

Diphenoxylate and Atropine is a Antidiarrheal medication tracked in Medicare Part D.

Is there a generic for Diphenoxylate and Atropine?

Yes. 8 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Diphenoxylate and Atropine?

Across 329 Part D plans, Diphenoxylate and Atropine averages $0.149/unit (NADAC). Lowest available: $0.149/unit. Highest in distribution: $0.149/unit.

Is Diphenoxylate and Atropine on the FDA shortage list?

No. Diphenoxylate and Atropine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antidiarrheal1 alternative in D1
01
Crofelemer
Brand: MYTESI
Lowest NADAC
0Generic mfrs
$11.8MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (9 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.